Mineralys Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.1 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 115.89% +0.12pp
- Institutions
- 294 +4
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 7 buys · 43 sells
| Name | Role | Stake |
|---|---|---|
| Jon Congleton | Chief Executive Officer | 0.44% |
| Eric Warren | Chief Commercial Officer | 0.04% |
| David Rodman | Former Chief Medical Officer | 0.01% |
| Daphne Karydas | Independent Director | 0.01% |
| Adam Levy | Chief Financial Officer | 0.00% |
| Glenn Sblendorio | Independent Chairperson | -- |
| Srinivas Akkaraju | Independent Director | -- |
| Kristine Peterson | Director | -- |
| James Ferguson | Chief Medical Officer | -- |
| RA Capital Management, L.P. | -- | -- |
| Lonnel Coats | Director | -- |
| Alexander Gold | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-18 | Kristine Peterson | Director | Other Acquisition | +12,400 | -- |
| 2026-10-18 | Kristine Peterson | Director | Other Derivative Acquisition | +16,600 | $20.92 |
| 2026-10-18 | Lonnel Coats | Director | Other Acquisition | +12,400 | -- |
| 2026-10-18 | Lonnel Coats | Director | Other Derivative Acquisition | +16,600 | $20.92 |
| 2026-10-12 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -3,542 | $22.04 |
| 2026-09-29 | Jon Congleton | Chief Executive Officer | Automatic Disposition | -75,000 | $25.46 |
| 2026-09-21 | Catalys Pacific | -- | Open Market Disposition | -104,320 | $28.81 |
| 2026-09-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $13.24–28.12 |
| 2026-09-16 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -417 | $27.95 |
| 2026-09-14 | Daphne Karydas | Independent Director | Derivative Exercise and Sale | -3,000 | $12.02–28.58 |
| 2026-09-13 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -7,709 | $28.14 |
| 2026-09-08 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -2,171 | $30.87 |
| 2026-08-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,437 | $13.24–25.98 |
| 2026-08-16 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -417 | $25.46 |
| 2026-08-12 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -14,056 | $26.48 |
| 2026-08-09 | James Ferguson | Chief Medical Officer | Other Acquisition | +102,400 | -- |
| 2026-08-09 | James Ferguson | Chief Medical Officer | Other Derivative Acquisition | +135,000 | $27.38 |
| 2026-08-09 | David Rodman | Former Chief Medical Officer | Derivative Exercise and Sale | -2,170 | $16.00–27.09 |
| 2026-07-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $13.24–26.87 |
| 2026-07-16 | David Rodman | Former Chief Medical Officer | Derivative Exercise and Sale | -416 | $15.44–26.53 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Mineralys Therapeutics discussion 0 comments